Thomas H. Mclain - 10 Jul 2023 Form 4 Insider Report for Renalytix plc (RNLXY)

Reporting relationship: President
Issuer ticker: RNLXY
Reported as of: 10 Jul 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jul 2023, 16:49:15 UTC
Prior SEC filing: 07 Jul 2023
Source filing: View source filing
Reporting owner signature: /s/ Katie Kazem, Attorney-in-Fact

Key filing fact

Thomas H. Mclain filed Form 4 for Renalytix plc (RNLXY) on 11 Jul 2023.

Key facts

This page summarizes Thomas H. Mclain's Form 4 filing for Renalytix plc (RNLXY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Jul 2023, 16:49.

Change

Previous filing in this sequence was filed on 07 Jul 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RNLX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +200,000
Change %
Price: $0.000000
Shares after: 200,000
Date: 10 Jul 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 200,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The exercise price is 1.175 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.506 using the Bank of England rate as of July 10, 2023 (1.00 pound sterling = $1.282).

Footnote F2

One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 10, 2023, subject to the Reporting Person's continuous service.